Compare Hims and Hers Health Inc (HIMS) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Kohl's Corporation — how do they compare? Hims and Hers Health Inc trades at $29.22 (market cap $6.55B), while Kohl's Corporation trades at $20.23 (market cap $2.28B). The key difference: Hims and Hers Health Inc is far larger — about 2.9× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.49% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Kohl's Corporation for 48 Days on average.
| HIMS | KSS | |
|---|---|---|
Market Cap | $6.55B | $2.28B |
Volume | 14,842,814 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $24.71 |
52-Week Low | $14.52 | $11.72 |
Typical Hold Time | 21 Days | 48 Days |
Enterprise Value | $7.25B | $7.88B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Kohl's (KSS) trades at $20.12, up 2.5% today, with a bullish technical signal driven by moving averages but overbought RSI readings. The stock shows deep value with a P/E of 8.63 and P/B of 0.55, though revenue has declined annually since 2022. Recent Q2 2026 earnings beat estimates with EPS of $1.28, and the company raised full-year guidance, supported by margin gains and a new chief merchandising officer appointment.
The outlook is mixed: low valuation and earnings momentum offer upside, but persistent sales declines and competitive pressures pose risks. Analyst consensus is cautious with a $15.50 price target below the current price, reflecting skepticism about the sustainability of the turnaround amid consumer spending shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
